[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346088-105":59,"doc-detail-346088-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","modeled-sojourn-time-and-sensitivity-for-detecting-preclinical-cancers-retrospectively-by-a-multicancer-early-detection-test","Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test","","Blood-based multicancer early detection tests offer clinical promise, yet key performance metrics such as sojourn time and sensitivity for detecting preclinical disease remain largely unknown. A retrospective evaluation used stored plasma from the American Cancer Society Cancer Prevention Study 3 (CPS3) to assess detectability prior to cancer diagnosis. Classical state-transition models were modified to characterize ctDNA shedding natural history and to estimate preclinical detectable duration and sensitivity via Bayesian likelihood. Results support detection of late-stage cancers through annual MCED screening.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modeled-sojourn-time-and-sensitivity-for-detecting-preclinical-cancers-retrospectively-by-a-multicancer-early-detection-test/346088/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modeled-sojourn-time-and-sensitivity-for-detecting-preclinical-cancers-retrospectively-by-a-multicancer-early-detection-test/346088.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding multicancer early detection tests?","Question",{"text":112,"@type":113},"The study targets the lack of known performance metrics—especially sojourn time and sensitivity—when detecting preclinical cancers using blood-based MCED tests.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the MCED test evaluated in this retrospective analysis?",{"text":117,"@type":113},"Stored plasma samples from CPS3 were tested retrospectively to assess detectability prior to cancer diagnosis, applying modified classical state-transition models.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main sensitivity findings for preclinical detectable windows?",{"text":121,"@type":113},"Across all stages, the test had 64% estimated overall sensitivity, and it showed 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346088,1790196094,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":8,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test  \nJames Y. Dai1, E. Georg Luebeck2, William D. Hazelton2, Christina A. Clarke1, Earl Hubbell1, and Alpa V. Patel3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Background: Blood-based multicancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting preclinical disease, are not yet known.\u003Cbr>Methods: In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study 3 (CPS3), GRAIL’s MCED test was evaluated for detectability prior to cancer diagnosis. Classical state-transition models for cancer screening were modified to characterize the natural history of ctDNAshedding cancers. The sensitivity estimand for detecting preclinical cancers by the MCED test was proposed in the context of retrospective testing, and a Bayesian likelihood method was developed to estimate preclinical detectable duration and sensitivity.\u003Cbr>Results: Analysis of CPS3 data showed that for the 12 prespecified cancers that represent two-thirds of cancer deaths in\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the United States, the test had 64% estimated overall sensitivity across all stages, and 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis. Untestable assumptions on state transition and sensitivity are discussed, along with limitations related to using stored plasma samples.\u003Cbr>Conclusions: State-transition models were developed for retrospective analysis of plasma samples from the CPS3 . Estimates for the length of the preclinical detectable window and the sensitivity at screening support annual MCED screening to intercept late-stage cancers.\u003Cbr>Impact: Retrospective analysis of plasma samples from the CPS3 supports the potential of GRAIL’s MCED test to detect cancers early in the preclinical state.\u003Cbr>See related In the Spotlight, p. 1484 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nCancer screening aims to detect cancers early in the preclinical phase, in order to provide better treatment options, improve quality of life, and prevent cancer death. The current paradigm that screens one cancer at a time has favorable benefit-to-harm trade-offs only for a few common cancers (e.g., breast; ref. 1, prostate; ref. 2, colorectal; ref. 3, and cervical cancer; ref. 4 and for lung cancer in the high-risk smoking population; ref. 5) . Achieving broad access and adherence to screening tests for some cancers currently recommended in the United States has already proved to be challenging, e.g., lung and colorectal cancers (6, 7) . For other cancers covering the majority of cancer deaths (8), such an approach is not costeffective for population-wide screening bec","cbCaibmHem854I1D","https://ap.wps.com/l/cbCaibmHem854I1D","pdf",2816970,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Impact\n# Introduction","[{\"question\":\"What problem does the study address regarding multicancer early detection tests?\",\"answer\":\"The study targets the lack of known performance metrics—especially sojourn time and sensitivity—when detecting preclinical cancers using blood-based MCED tests.\"},{\"question\":\"How was the MCED test evaluated in this retrospective analysis?\",\"answer\":\"Stored plasma samples from CPS3 were tested retrospectively to assess detectability prior to cancer diagnosis, applying modified classical state-transition models.\"},{\"question\":\"What were the main sensitivity findings for preclinical detectable windows?\",\"answer\":\"Across all stages, the test had 64% estimated overall sensitivity, and it showed 43% sensitivity during an average 1.36-year preclinical detectable window before metastasis.\"}]","Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test | PDF",1790060034,25,[146],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/c6d41cced3fd5d004902b0eee418e753.webp",983,1315]